268 related articles for article (PubMed ID: 26629855)
1. Covalent targeting of acquired cysteines in cancer.
Visscher M; Arkin MR; Dansen TB
Curr Opin Chem Biol; 2016 Feb; 30():61-67. PubMed ID: 26629855
[TBL] [Abstract][Full Text] [Related]
2. Targeting Kras
Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
[TBL] [Abstract][Full Text] [Related]
3. Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S).
Zhang Z; Guiley KZ; Shokat KM
Nat Chem Biol; 2022 Nov; 18(11):1177-1183. PubMed ID: 35864332
[TBL] [Abstract][Full Text] [Related]
4. Structure-based inhibitor design of mutant RAS proteins-a paradigm shift.
Nyíri K; Koppány G; Vértessy BG
Cancer Metastasis Rev; 2020 Dec; 39(4):1091-1105. PubMed ID: 32715349
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
Tang D; Kroemer G; Kang R
Mol Cancer; 2021 Oct; 20(1):128. PubMed ID: 34607583
[TBL] [Abstract][Full Text] [Related]
6. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
[TBL] [Abstract][Full Text] [Related]
7. KRAS: From undruggable to a druggable Cancer Target.
Uprety D; Adjei AA
Cancer Treat Rev; 2020 Sep; 89():102070. PubMed ID: 32711246
[TBL] [Abstract][Full Text] [Related]
8. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS.
Schulze CJ; Seamon KJ; Zhao Y; Yang YC; Cregg J; Kim D; Tomlinson A; Choy TJ; Wang Z; Sang B; Pourfarjam Y; Lucas J; Cuevas-Navarro A; Ayala-Santos C; Vides A; Li C; Marquez A; Zhong M; Vemulapalli V; Weller C; Gould A; Whalen DM; Salvador A; Milin A; Saldajeno-Concar M; Dinglasan N; Chen A; Evans J; Knox JE; Koltun ES; Singh M; Nichols R; Wildes D; Gill AL; Smith JAM; Lito P
Science; 2023 Aug; 381(6659):794-799. PubMed ID: 37590355
[TBL] [Abstract][Full Text] [Related]
9. Discoveries in the redox regulation of KRAS.
Kramer-Drauberg M; Ambrogio C
Int J Biochem Cell Biol; 2021 Feb; 131():105901. PubMed ID: 33309959
[TBL] [Abstract][Full Text] [Related]
10. KRAS Alleles: The Devil Is in the Detail.
Haigis KM
Trends Cancer; 2017 Oct; 3(10):686-697. PubMed ID: 28958387
[TBL] [Abstract][Full Text] [Related]
11. Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue.
Perurena N; Cichowski K
Cancer Cell; 2024 Jun; 42(6):943-945. PubMed ID: 38861932
[TBL] [Abstract][Full Text] [Related]
12. Targeting Mutant KRAS for Anticancer Therapy.
Chen F; Alphonse MP; Liu Y; Liu Q
Curr Top Med Chem; 2019; 19(23):2098-2113. PubMed ID: 31475898
[TBL] [Abstract][Full Text] [Related]
13. Exploring Targeted Degradation Strategy for Oncogenic KRAS
Zeng M; Xiong Y; Safaee N; Nowak RP; Donovan KA; Yuan CJ; Nabet B; Gero TW; Feru F; Li L; Gondi S; Ombelets LJ; Quan C; Jänne PA; Kostic M; Scott DA; Westover KD; Fischer ES; Gray NS
Cell Chem Biol; 2020 Jan; 27(1):19-31.e6. PubMed ID: 31883964
[TBL] [Abstract][Full Text] [Related]
14. NMR in integrated biophysical drug discovery for RAS: past, present, and future.
Marshall CB; KleinJan F; Gebregiworgis T; Lee KY; Fang Z; Eves BJ; Liu NF; Gasmi-Seabrook GMC; Enomoto M; Ikura M
J Biomol NMR; 2020 Nov; 74(10-11):531-554. PubMed ID: 32804298
[TBL] [Abstract][Full Text] [Related]
15. Drug Discovery by Targeting Mutant KRAS.
Ye N
Curr Top Med Chem; 2019; 19(23):2079-2080. PubMed ID: 31762422
[No Abstract] [Full Text] [Related]
16. Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.
Huynh MV; Campbell SL
Mini Rev Med Chem; 2016; 16(5):383-90. PubMed ID: 26423694
[TBL] [Abstract][Full Text] [Related]
17. Hitting KRAS When It's Down.
Gabizon R; London N
J Med Chem; 2020 Jul; 63(13):6677-6678. PubMed ID: 32568546
[TBL] [Abstract][Full Text] [Related]
18. KRAS as a Therapeutic Target.
McCormick F
Clin Cancer Res; 2015 Apr; 21(8):1797-801. PubMed ID: 25878360
[TBL] [Abstract][Full Text] [Related]
19. Improving Prospects for Targeting RAS.
Singh H; Longo DL; Chabner BA
J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
[TBL] [Abstract][Full Text] [Related]
20. Small molecule inhibitors of RAS proteins with oncogenic mutations.
Orgován Z; Keserű GM
Cancer Metastasis Rev; 2020 Dec; 39(4):1107-1126. PubMed ID: 32770300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]